PAVmed (NASDAQ:PAVM) Stock Falls 7.3% – Time to Sell?

PAVmed Inc. (NASDAQ:PAVM)’s share price fell 7.3% during trading on Monday. The stock traded as low as $2.66 and last traded at $2.66. 7,386 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 31,706 shares. The stock had previously closed at $2.87.

Analyst Ratings Changes

Separately, Weiss Ratings lowered PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, PAVmed presently has an average rating of “Hold” and a consensus target price of $56.00.

PAVmed Stock Up 0.4%

The business has a 50 day simple moving average of $4.53 and a 200 day simple moving average of $6.09. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market cap of $21.36 million, a PE ratio of -0.17 and a beta of 0.69.

Institutional Investors Weigh In On PAVmed

A hedge fund recently bought a new stake in PAVmed stock. Two Seas Capital LP acquired a new stake in shares of PAVmed Inc. (NASDAQ:PAVM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 461,539 shares of the company’s stock, valued at approximately $2,742,000. Two Seas Capital LP owned approximately 46.15% of PAVmed as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a medical device and diagnostics company focused on developing and commercializing technologies intended to improve the diagnosis and treatment of serious medical conditions. The company operates through subsidiaries and strategic business units that address areas including cancer detection, remote patient monitoring, vascular access and minimally invasive procedures.

One of PAVmed’s primary businesses is its majority-owned subsidiary Lucid Diagnostics, which developed the EsoGuard DNA test and EsoCheck cell-collection device.